Neurology News

US FDA Approves Rechargeable Deep Brain Stimulation Device for Movement Disorders

The US Food and Drug Administration (FDA) has approved a rechargeable deep brain stimulation device for patients with Parkinson disease (PD), essential tremor, dystonia, and epilepsy.

The Percept™ RC Deep Brain Stimulation (DBS) system, developed by Medtronic, uses a surgically implanted medical device that is similar to a cardiac pacemaker and delivers precise electrical signals through thin wires to specific brain targets via BrainSense™ technology, according to the company’s news release.

The Percept™ RC battery has a service life of at least 15 years. Patients can fully recharge the device from 10% to 90% in less than an hour.

An estimated 70 percent of patients eligible for DBS require a magnetic resonance imaging (MRI) scan as part of their essential care, and the DBS system can offer patients access to 3T scans and best-in-class 1.5T MRI scan labeling, according to the company.

The company has intended for the rechargeable DBS system to provide valuable insights for health care providers to customize therapy based on a patient’s evolving needs.

“Our DBS therapy with exclusive BrainSense™ technology can help control debilitating tremors for people living with Parkinson’s, providing patients with the ability to physically engage in everyday moments — something many of us unintentionally take for granted,” said Amaza Reitmeier, vice president and general manager of brain modulation at Medtronic, in the news release.


FDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology. News release. Medtronic. January 08, 2024. Accessed January 09, 2024.